Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Benjamin L. Ebert, M.D., D.Phil.

Co-Author

This page shows the publications co-authored by Benjamin Ebert and Max Jan.
Connection Strength

3.695
  1. Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. Nat Rev Clin Oncol. 2021 Mar 02.
    View in: PubMed
    Score: 0.983
  2. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci Transl Med. 2021 Jan 06; 13(575).
    View in: PubMed
    Score: 0.973
  3. Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Adv. 2019 07 23; 3(14):2199-2204.
    View in: PubMed
    Score: 0.879
  4. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature. 2020 09; 585(7824):293-297.
    View in: PubMed
    Score: 0.233
  5. A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. Blood Adv. 2020 02 11; 4(3):445-448.
    View in: PubMed
    Score: 0.228
  6. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019 07 11; 134(2):160-170.
    View in: PubMed
    Score: 0.216
  7. Clonal hematopoiesis. Semin Hematol. 2017 01; 54(1):43-50.
    View in: PubMed
    Score: 0.182
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.